Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

被引：1

作者：

Brahmer, Julie R.

Horn, Leora

Antonia, Scott J.

Spigel, David R.

Gandhi, Leena

Sequist, Lecia V.

Sankar, Vindira

Ahlers, Christoph Matthias

Wigginton, Jon M.

Kollia, Georgia

Gupta, Ashok Kumar

Gettinger, Scott N.

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Bristol Myers Squibb Co, Princeton, NJ USA

[8] Yale Univ, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8030

引用

页数：1

共 50 条

[31] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
Amin, Asim
Plimack, Elizabeth R.
Infante, Jeffrey R.
Ernstoff, Marc S.
Rini, Brian I.
McDermott, David F.
Knox, Jennifer J.
Pal, Sumanta Kumar
Voss, Martin Henner
Sharma, Padmanee
Kollmannsberger, Christian K.
Heng, Daniel Yick Chin
Spratlin, Jennifer L.
Shen, Yun
Kurland, John F.
Gagnier, Paul
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)
Rizvi, Naiyer A.
Antonia, Scott J.
Chow, Laura Quan Man
Brahmer, Julie R.
Juergens, Rosalyn A.
Borghaei, Hossein
Shepherd, Frances A.
Laurie, Scott Andrew
Gerber, David E.
Goldman, Jonathan Wade
Shen, Yun
Harbison, Christopher
Alaparthy, Suresh
Chen, Allen C.
Gettinger, Scott N.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
Rizvi, N. A.
Shepherd, F. A.
Antonia, S. J.
Brahmer, J. R.
Chow, L. Q.
Goldman, J.
Juergens, R.
Borghaei, H.
Ready, N. E.
Gerber, D. E.
Shen, Y.
Harbison, C.
Chen, A. C.
Gettinger, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S31 - S31
[34] Combined nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab in the treatment of advanced melanoma (MEL) patients (pts): Safety and clinical activity
Sznol, M.
Callahan, M. K.
Kluger, H.
Postow, M. A.
Burke, M.
Hong, Q.
Selby, M.
Korman, A.
Gupta, A.
Wolchok, J. D.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S866 - S866
[35] Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
Callahan, Margaret K.
Horak, Christine E.
Curran, Michael A.
Hollman, Travis
Schaer, David A.
Yuan, Jianda
Lesokhin, Alexander M.
Kitano, Shigehisa
Hong, Quan
Ariyan, Charlotte Eielson
Busam, Klaus J.
Feely, William
Jure-Kunkel, Maria
Grosso, Joseph
Simon, Jason S.
Korman, Alan J.
Wigginton, Jon M.
Gupta, Ashok Kumar
Sznol, Mario
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[36] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC)
Amin, A.
Plimack, E. R.
Infante, J. R.
Ernstoff, M. S.
Rini, B.
Mcdermott, D. F.
Knox, J.
Pal, S. K.
Voss, M. H.
Sharma, P.
Kollmannsberger, C.
Heng, D. Y. C.
Spratlin, J.
Shen, Y.
Kurland, J. F.
Gagnier, P.
Hammers, H.
BJU INTERNATIONAL, 2014, 114 : 2 - 2
[37] A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).
Amin, Asirn
Ernstoff, Marc S.
Infante, Jeffrey R.
Heng, Daniel Yick Chin
Rini, Brian I.
Plimack, Elizabeth R.
McDermott, David F.
Kollmannsberger, Christian K.
Reaume, Martin Neil
Spratlin, Jennifer L.
Knox, Jennifer J.
Voss, Martin Henner
Pal, Sumanta Kumar
Shen, Yuri
Dhar, Arindarn
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis
Sangro, Bruno
Crocenzi, Todd S.
Welling, Theodore Hobart
Inarrairaegui, Mercedes
Prieto, Jesus
Fuertes, Carmen
Delanty, Laurie
Feely, William
Anderson, Jeffrey
Grasela, Dennis M.
Wigginton, Jon M.
Gupta, Ashok Kumar
Melero, Ignacio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[39] Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
Michael A Postow
Diana M Cardona
Janis M Taube
Robert A Anders
Clive R Taylor
Jedd D Wolchok
Margaret K Callahan
Michael A Curran
Alexander M Lesokhin
Joseph F Grosso
Christine E Horak
John Cogswell
Jason S Simon
Ashok K Gupta
Mario Sznol
Journal of Translational Medicine, 12 (Suppl 1)
[40] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.
Motzer, Robert John
Bono, Petri
Hudes, Gary R.
Tomita, Yoshihiko
Ravaud, Alain
Waxman, Ian
Gore, Martin Eric
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →